Enlivex Therapeutics Ltd.
ENLV
$1.10
$0.065.77%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 2.06M | 771.00K | 987.00K | 1.09M | 1.64M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 5.48M | 3.12M | 2.99M | 3.95M | 6.09M |
| Operating Income | -5.48M | -3.12M | -2.99M | -3.95M | -6.09M |
| Income Before Tax | -5.18M | -2.60M | -3.10M | -4.14M | -9.10M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -5.18M | -2.60M | -3.10M | -4.14M | -9.10M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -5.18M | -2.60M | -3.10M | -4.14M | -9.10M |
| EBIT | -5.48M | -3.12M | -2.99M | -3.95M | -6.09M |
| EBITDA | -5.45M | -2.96M | -2.83M | -3.76M | -5.89M |
| EPS Basic | -0.23 | -0.12 | -0.16 | -0.22 | -0.49 |
| Normalized Basic EPS | -0.12 | -0.08 | -0.10 | -0.13 | -0.16 |
| EPS Diluted | -0.23 | -0.12 | -0.16 | -0.22 | -0.49 |
| Normalized Diluted EPS | -0.12 | -0.08 | -0.10 | -0.13 | -0.16 |
| Average Basic Shares Outstanding | 22.49M | 21.28M | 19.55M | 18.73M | 18.60M |
| Average Diluted Shares Outstanding | 22.49M | 21.28M | 19.55M | 18.73M | 18.60M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |